Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | OGG1 | O15527 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242290 | 0.82 | HPGD (0.70) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL1164220 | 0.76 | TRPA1 (0.50) | HTTCA12MMP2CA14LMNA | |
| SCHEMBL1923460 | 0.76 | CA12 (0.54) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL1164028 | 0.72 | TRPA1 (0.55) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL11604284 | 0.72 | KDM4E (0.54) | HPGDHTTLMNAALDH1A1TRPA1 | |
| SCHEMBL13062204 | 0.71 | ALDH1A1 (0.64) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL21241696 | 0.70 | CA12 (0.56) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL26263205 | 0.70 | ALDH1A1 (0.54) | CA12MMP2CA14LMNAALDH1A1 | |
| SCHEMBL966937 | 0.70 | HTT (0.58) | HPGDHTTCA12MMP2CA14 | |
| SCHEMBL12706071 | 0.70 | ALDH1A1 (0.71) | HPGDHTTCA12MMP2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2464629-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Allergan, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8168795-B2 | Selective sphingosine-1-phosphate receptor antagonists | ALLERGAN, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168795-B2 | Selective sphingosine-1-phosphate receptor antagonists | ALLERGAN, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168795-B2 | Selective sphingosine-1-phosphate receptor antagonists | ALLERGAN, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2011028927-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011019681-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | HPGD 3667/4885HTT 3427/4885CA12 4826/4885 |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | HPGD 3667/4885HTT 3427/4885CA12 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.